Prevalence and prognostic value of conduction disturbances at the time of diagnosis of cardiac AL amyloidosis

Annals of Noninvasive Electrocardiology

Volumn 18, Issue 4, 2013, Pages 327-335

  Boldrini, Michele ^a   Salinaro, Francesco ^a   Mussinelli, Roberta ^a   Raimondi, Ambra ^a   Alogna, Alessio ^a   Musca, Francesco ^a   Palladini, Giovanni ^a   Merlini, Giampaolo ^a   Perlini, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

amyloid; conduction disturbances; echocardiography; electrocardiography; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART AMYLOIDOSIS; HEART MUSCLE CONDUCTION DISTURBANCE; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; QT PROLONGATION;

AMYLOID; CONDUCTION DISTURBANCES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; PROGNOSIS;

AGE DISTRIBUTION; AGED; AMYLOIDOSIS; ANALYSIS OF VARIANCE; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; COHORT STUDIES; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 84880834855     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/anec.12032     Document Type: Article

References (45)

1. Merlini G, Bellotti V., Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596.
2. Falk RH., Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047-2060.
3. Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective. Eur Heart J 2012 Jun 28 [Epub ahead of print].
4. Merlini G, Stone MJ., Dangerous small B-cell clones. Blood 2006; 108: 2520-2530.
5. Kyle RA, Greipp PR., Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58: 665-683.
6. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. Circulation 2009; 120: 1203-1212.
7. Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2012 Sept 14 [Epub ahead of print].
8. Hesse A, Altland K, Linke RP, et al. Cardiac amyloidosis: A review and report of a new transthyretin (prealbumin) variant. Br Heart J 1993; 70: 111-115.
9. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998; 91: 141-157.
10. Buja LM, Khoi NB, Roberts WC., Clinically significant cardiac amyloidosis. Clinicopathologic findings in 15 patients. Am J Cardiol 1970; 26: 394-405.
11. Roberts WC, Waller BF., Cardiac amyloidosis causing cardiac dysfunction: Analysis of 54 necropsy patients. Am J Cardiol 1983; 52: 137-146.
12. Falk RH, Rubinow A, Cohen AS., Cardiac arrhythmias in systemic amyloidosis: Correlation with echocardiographic abnormalities. J Am Coll Cardiol. 1984; 3: 107-113.
13. Das MK, Khan B, Jacob S, et al. Significance of a fragmented QRS complex versus a Q wave in patients with coronary artery disease. Circulation 2006; 113: 2495-2501.
14. Shadaksharappa KS, Kalbfleisch JM, Conrad LL, et al. Recognition and significance of intraventricular block due to myocardial infarction (peri-infarction block). Circulation 1968; 37: 20-26.
15. Perlini S, Salinaro F, Cappelli F, et al. Prognostic value of fragmented QRS in cardiac AL amyloidosis. Int J Cardiol 2012 Jun 27 [Epub ahead of print].
16. Falk RH, Dubrey SW., Amyloid heart disease. Prog Cardiovasc Dis 2010; 52: 347-361.
17. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95: 535-537.
18. Kristen AV, Perz JB, Schonland SO, et al. Non-invasive predictors of survival in cardiac amyloidosis. Eur J Heart Fail 2007; 9: 617-624.
19. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005; 165: 1425-1429.
20. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol 1997; 30: 1046-1051.
21. Hamer JP, Janssen S, van Rijswijk MH, et al. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13: 623-627.
22. Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol 2000; 85: 849-853.
23. Hoigne P, Attenhofer Jost CH, Duru F, et al. Simple criteria for differentiation of Fabry disease from amyloid heart disease and other causes of left ventricular hypertrophy. Int J Cardiol 2006; 111: 413-422.
24. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445.
25. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
26. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-1789.
27. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328.
28. Gertz MA, Merlini G., Definition of organ involvement and response to treatment in AL amyloidosis: An updated consensus opinion. Amyloid 2010; 17: 48-49.
29. Palladini G, Perlini S, Merlini G,. Imaging of systemic amyloidosis. In, Gertz MA, Rajkumar SV, (eds.): Amyloidosis. Diagnosis and Treatment, Humana Press, 2010, pp. 15-32.
30. Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426-3430.
31. Ghio S, Perlini S, Palladini G, et al. Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 2007; 9: 808-813.
32. Cappelli F, Porciani MC, Bergesio F, et al. Right ventricular function in AL amyloidosis: Characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging 2012; 13: 416-422.
33. Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol 2012; 87: 465-471.
34. Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008; 15: 40-48.
35. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
36. Perlini S, Muiesan ML, Cuspidi C, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103: 678-683.
37. de Simone G, Devereux RB, Koren MJ, et al. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93: 259-265.
38. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices-Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Am Coll Cardiol 2002; 40: 1703-1719.
39. Mathew V, Olson LJ, Gertz MA, et al. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol 1997; 80: 1491-1492.
40. Hess EP, White RD., Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: Presenting rhythms, management and outcomes in four patients. Resuscitation 2004; 60: 105-111.
41. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5: 235-240.
42. Leone O, Longhi S, Quarta CC, et al. New pathological insights into cardiac amyloidosis: Implications for non-invasive diagnosis. Amyloid 2012; 19: 99-105.
43. Kawashima T, Sasaki H., Gross anatomy of the human cardiac conduction system with comparative morphological and developmental implications for human application. Ann Anat 2011; 193: 1-12.
44. Merlini G, Seldin DC, Gertz MA., Amyloidosis: Pathogenesis and new therapeutic options. J Clin Oncol 2011; 29: 1924-1933.
45. Falk RH., Cardiac amyloidosis: A treatable disease, often overlooked. Circulation 2011; 124: 1079-1085.